Since non-insulin-dependent diabetic (NIDDM) patients represent a high-risk group, the benefits of their drug treatment must be carefully weighed against potential risks. Sulphonylureas are generally well-tolerated with few non-specific adverse effects. Less than 2 % of patients discontinue treatment because of side-effects. Hypoglycaemia is the most common adverse effect (usually mild) and is related to several predisposing factors. Risk of hypoglycaemia is highest within the first month of treatment (5.6 % of glibenclamide-treated patients compared with 1.7 % for glimepiride, a sulphonylurea of the new generation, based on a recent study). Sulphonylureas in reduced doses, can be given, with caution, to patients with liver and renal disease. Metformin, a biguanide drug, used alone does not produce severe hypoglycaemia under normal circumstances. Gastrointestinal reactions are the most common side-effects, leading to discontinuation of treatment in approximately 4 % of cases. Lactic acidosis is a rare but serious metabolic side-effect of biguanide treatment and its risk increases with age and renal dysfunction. Therefore, in elderly patients, renal function should be monitored regularly and metformin is contraindicated in patients, with renal disease or dysfunction. Although still controversial, both sulphonylureas and biguanides bear a special warning for an increased risk of cardiovascular mortality based on the University Group Diabetes Program study in the USA. Acarbose is not associated with life-threatening adverse effects. Its main side-effects are gastrointestinal symptoms in more than 50 % of patients resulting in discontinuation in less than 5 %. At high doses, serum transaminases should be monitored for the first 6 months of treatment. A list of contraindications, mostly gastrointestinal and hepatic diseases, should be maintained.
When diet and education have failed to achieve a good metabolic control in non-insulin-dependent diabetic (NIDDM) patients, oral antidiabetic treatment should be started. First-line drugs are sulphonylureas, biguanides and a -glucosidase inhibitors. A combination of small doses of different drugs including insulin may be used to avoid side effects [1] . Since prevalence of NIDDM increases with age, obesity and dyslipoproteinaemia this population is at high risk for cardiovascular disease and hypertension. Age-specific mortality in these patients is twice that of the general population [2] . Therefore, the benefit of drug treatment in this group of patients must carefully be compared with the possible risks, especially for long-term treatment such as the oral hypoglycaemic agents.
Sulphonylureas
Sulphonylureas have been used in the management of diabetes for 40 years and numerous publications describing their safety and efficacy are available. About 25 years after the introduction of the original compounds (carbutamide, tolbutamide, chlorpropamide), the second-generation sulphonylureas, with greater hypoglycaemic potency per milligram were introduced into clinical practice. Glimepiride is a novel sulphonylurea currently being registered worldwide but is included in this review because of its novel characteristics. Sulphonylureas are still the most-frequently prescribed oral hypoglycaemic agents, testimony to both their acceptable blood glucose-lowering efficacy and general safety. An overview is given in Table 1 .
In general, sulphonylureas are extremely well-tolerated. Gastrointestinal, dermatologic and haematologic reactions are rare and less than 2 % of patients discontinue therapy due to side-effects [4] . Placebocontrolled studies with glimepiride showed similar patterns of adverse events with differences between placebo and the sulphonylurea only for the incidence of hypo-and hyperglycaemia (Table 2) .
Hypoglycaemia is by far the most common side-effect of all sulphonylureas. Chlorpropamide and glibenclamide (drugs with a longer duration) are accused of being especially liable to produce hypoglycaemia [5] : in a recent review, chlorpropamide and glibenclamide accounted for 70 % of all severe hypoglycaemic episodes. Since glibenclamide is the most frequently prescribed sulphonylurea, however, the frequency of drug-induced hypoglycaemia is dependent on the actual prescription figure. If the rate of hypoglycaemia is assessed as "hypoglycaemia per million defined daily doses", data from the Swedish Drug Information System between 1980 and 1987 show that glibenclamide overall produces less hypoglycaemia than chlorpropamide and glipizide [6] . In any case, the majority of all hypoglycaemic episodes with sulphonylureas are mild in nature and the incidence of severe episodes has been estimated at 0.19-0.25 per 1000 patient-years [7, 8] , while the incidence with insulin therapy was approximately 400 times higher [4] . Mortality in these two reviews of sulphonylurea therapy was calculated as 0.014 to 0.033 per 1000 patient-years, corresponding to a mortality rate of approximately 10 %.
Comparative studies between sulphonylureas are frequently published, but in most instances have limitations, since patient numbers are small or the studies are not double-blind [9] . One open, randomized study, of 2520 patients, is the UKPDS comparing chlorpropamide with glibenclamide treatment amongst other objectives. After 3 years with similar efficacy, the rate of hypoglycaemic episodes of any severity was 13.5 % with chlorpropamide and 27.8 % with glibenclamide. This higher incidence was mainly due to minor hypoglycaemic attacks since similar rates were seen for major episodes. However, the drop-out rate due to side effects was 13 % for chlorpropamide and only for 7 % with glibenclamide [10] . Thus, a positive selection for chlorpropamide patients during the study could have influenced the endpoint results for hypoglycaemia. Double-blind studies have been performed for the registration of the new sulphonylurea drug glimepiride. In a 1 year, doubleblind comparison study in 1044 patients, 150 episodes of hypoglycaemia occurred in 14 % of glibenclamide 
Biguanides
Biguanides differ radically in their chemical structure from sulphonylureas and, therefore, the adverse effects associated with their use are quite different. In contrast to sulphonylureas, therapeutic doses of metformin do not cause hypoglycaemia and do not lower blood glucose in non-diabetic subjects [12] . The major risk of biguanide therapy is lactic acidosis, a metabolic condition with a mortality of about 50 %. The reported incidence of lactic acidosis in metformin treated patients is approximately 0.03 per 1000 patient-years (compared to a rate of 0.64 per 1000 patient-years with phenformin) [13] . Since the risk of lactic acidosis increases with the degree of renal dysfunction and the patient's age, the renal function of older patients has to be monitored regularly. Metformin, therefore, is contraindicated in patients with renal disease as defined by serum creatinine levels ≥ 130 m mol/l (men) or ≥ 120 m mol/l (women). Monitoring of renal function is especially important in NIDDM patients, since advanced age in general is associated with a reduced renal function, and 10-20 % of all NIDDM patients develop proteinuria during the first 5 years after hyperglycaemia is diagnosed suggesting the presence of a glomerular disease other than diabetic nephropathy in these patients [14, 15] .
The most common side effects (5-20 % of patients) are gastrointestinal: anorexia, nausea, abdominal discomfort and diarrhoea [16, 12] leading to withdrawal of the drug in less than 5 % of patients. Impaired gastrointestinal absorption of vitamin B 12 and folate are rare [12, 16] .
Cardiovascular risk with biguanides and sulphonylureas
A long-term prospective study was conducted by the University Group Diabetes Program (UGDP) to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in 1027 patients with NIDDM. Results showed that patients treated for 5 to 8 years with diet plus tolbutamide (1.5 g per day) or phenformin (100 mg per day) had a rate of cardiovascular mortality approximately 2.5 times that of patients treated with diet alone. Total mortality was increased in both treatment groups (statistically significant only for the phenformin group). These data resulted in a premature discontinuation of both treatment groups [17, 18] . Despite considerable controversy regarding the interpretation of these results [19] , the findings of the UGDP study provide a basis for a warning of cardiovascular mortality in the USA for all sulphonylureas and metformin. Renewed interest in this study came from animal studies showing that sulphonylureas impair the recovery of the myocardial function and increase the ultimate infarct size. The mechanism behind this effect is a blocking of cardiovascular K ATP channels resulting in the inhibition of physiological adaptive measures to protect the myocardium [20] . In this respect, glimepiride has a distinctive feature since, unlike glibenclamide, the diazoxide-induced vasodilatation in the human forearm vascular bed is not inhibited by glimepiride [20] indicating no interaction with cardiovascular K ATP channels.
a -glucosidase inhibitors
The a -glucosidase inhibitors reversibly inhibit intestinal a -glucosidase enzymes within the intestinal brush border, thereby delaying the digestion of complex carbohydrates and disaccharides to absorbable monosaccharides. This results in attenuating postprandial blood glucose peak and lowering of postprandial and fasting blood glucose levels in NIDDM patients.
Gastrointestinal problems are the most common side-effects reported in human studies with these drugs. Symptoms are caused by fermentation of unabsorbed carbohydrate in the bowel, which results in increased gas production. In the phase III studies performed in the USA, 76 % of acarbose-treated patients and 37 % of placebo-treated patients, reported adverse events affecting the digestive system [21] . If one compares this with the incidence of digestive symptoms in the placebo-group in the Hoechst AG studies with glimepiride, the difference in frequency of flatulence for example, is striking (29 % in the placebo group acarbose vs 0.4 % in placebo group glimepiride) ( Table 3) . This difference may be readily explained by the awareness of patients in acarbose trials concerning this possible side-effect.
The incidence of gastrointestinal side-effects tend to decrease with combined treatment [22, 23] , possibly due to an adequate diet rich in complex carbohydrates and low in simple sugars and individual acarbose doses needed to achieve desirable postprandial blood glucose values [24] . The withdrawal rate in the USA acarbose studies was 15 % in acarbose patients compared with 5 % in the placebo group [21] . The figures for the placebo-controlled patients in the Bayer International Clinical Data Pool (1646 patients) show that 78 (4.7 %) of acarbose-treated patients compared with only 33 (2 %) of the placebo patients withdrew, mainly because of gastrointestinal side effects [21] . Contraindications to acarbose treatment include intestinal malabsorption syndromes, inflammatory bowel disease, intestinal obstruction, hepatic disease and moderate or severe renal impairment [25] .
Conclusion
There are three major classes of oral antidiabetic drugs: the sulphonylureas, biguanides and a -glucosidase inhibitors, and all have their own typical safety profiles. Their general role in treatment of NIDDM is well-established. On an individual basis a risk/ benefit estimation should be made to decide which drug should be used. 
